|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's range||36.20 - 39.21|
|52-week range||16.55 - 42.01|
|Beta (5Y monthly)||1.57|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||39.38|
With me today are John Nicols, Codexis' President and Chief Executive Officer; and Ross Taylor, Codexis' Chief Financial Officer. During this call, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2021 total revenues, our updated guidance on product revenues and gross margin on product revenues, and our expectations regarding sales of one of our proprietary enzymes to Pfizer for the manufacture of their late clinical state COVID-19 antiviral therapeutic candidate.
Codexis (CDXS) delivered earnings and revenue surprises of 133.33% and 27.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.